Table 6.
Analysis of clinical, immunological characteristics and immunosuppressive therapy as predictors for AR in AR versus none AR cases
| Variables | AR group N = 36 |
Non-AR N = 47 |
OR (95% CI) |
P
Value |
||
|---|---|---|---|---|---|---|
| Age at transplant | Mean ± SD | 9.4 (3.2%) | 10 ± 2.8 | 0.953(0.819–1.109) | 0.535 | |
| Sex | Male | N (%) | 30 (83.3%) | 35 (74.5%) | Reference | - |
| Female | N (%) | 6 (16.7%) | 12 (25.5%) | 0.552(0.183–1.66) | 0.290 | |
| Original kidney disease | NONE CAKUT | N (%) | 17 (47.2%) | 24 (51.1%) | Reference | - |
| CAKUT | N (%) | 19 (52.8%) | 23 (48.9%) | 1.101 (0.640–1.893) | 0.744 | |
| Dialysis before Tx | No | N (%) | 2 (5.6%) | 2 (4.3%) | Reference | - |
| Yes | N (%) | 34 (94.4%) | 45 (95.7%) | 1.324(0.177–9.877) | 0.785 | |
| Dialysis duration (months) | Median, IQR | 12 (2–60) | 12 (1–60) | 0.979(0.936–1.025) | 0.366 | |
| Donor/recipient HLA mismatch | 4/6 | N (%) | 0 | 3 (6.4) | Reference | - |
| 3/6 | N (%) | 22 (61.1) | 28 (59.6) | - | 0.1 | |
| 2/6 | N (%) | 12 (33.3) | 13 (27.7) | - | 0.1 | |
| 1/6 | N (%) | 2 (5.6) | 1 (2.1) | - | 0.1 | |
| 0/6 | N (%) | 0 | 2 (4.3) | - | - | |
| CMV risk stratification* | Low risk | N (%) | 5 (13.9%) | 3 (6.4%) | Reference | - |
| Intermediate | N (%) | 30 (83.3%) | 40 (85.1%) | 0.607(0.239–1.543) | 0.295 | |
| High risk | N (%) | 1 (2.8%) | 4 (8.5%) | 0.313(0.068–1.452) | 0.138 | |
| Antibody induction | Basiliximab | N (%) | 15 (41.7%) | 28 (59.6%) | Reference | - |
| ATG | N (%) | 21 (58.3%) | 19 (40.4%) | 1.57(0.909–2.714) | 0.106 | |
| Preemptive PEX | NO | N (%) | 32 (88.9%) | 36 (76.6%) | Reference | - |
| Yes | N (%) | 4 (11.1%) | 11 (23.4%) | 0.577(0.275–1.215) | 0.148 | |
| Maintenance IS other than TAC | MMF | N (%) | 36 (100%) | 46 (97.9%) | - | 0.379 |
| Azathioprine | N (%) | 0 (0%) | 1 (2.1%) | |||
AR; acute rejection, N; number, SD; standard deviation, IQR; interquartile range, CAKUT; congenital anomalies of kidney and urinary tract, CMV; cytomegalo virus, HLA; human leukocytic antigen, ATG: anti thymocyte globulin, PEX; plasma exchange, IS; immunosuppressive, TAC; tacrolimus, MMF; mycophenolic mofetil.* CMV IgG: Low risk (D -, R -), intermediate risk either (D+, R+) or (D-, R+), high risk (D+, R-), Logistic regression analysis test was used for statistical analysis